2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma
Company Announcements

2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma

An update from 2seventy bio (TSVT) is now available.

2seventy bio, Inc. and Bristol Myers Squibb have announced the FDA approval of Abecma, a new treatment for adult patients with relapsed or refractory multiple myeloma who have previously undergone at least two other therapies. This groundbreaking decision, based on the successful outcome of the Phase 3 KarMMa-3 trial, marks a significant advancement for patients battling this challenging form of cancer.

For detailed information about TSVT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated Newsdesk2seventy bio Halts KarMMa-9 Study, Forecasts Strong Abecma Sales
TheFly2seventy Bio to discontinue enrollment in Phase 3 KarMMa-9 study of Abecma
TheFly2seventy Bio sees Q3 Abecma U.S. revenue growth ~ 30% vs. Q2
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App